|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Lund AH and van Lohuizen M: Epigenetics
and cancer. Genes Dev. 18:2315–2335. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Taniguchi H, Yamamoto H, Akutsu N, et al:
Transcriptional silencing of hedgehog-interacting protein by CpG
hypermethylation and chromatic structure in human gastrointestinal
cancer. J Pathol. 213:131–139. 2007. View Article : Google Scholar
|
|
4.
|
Zhang C, Li H, Zhou G, et al:
Transcriptional silencing of the TMS1/ASC tumour suppressor gene by
an epigenetic mechanism in hepatocellular carcinoma cells. J
Pathol. 212:134–142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Wei Y, Xia W, Zhang Z, et al: Loss of
trimethylation at lysine 27 of histone H3 is a predictor of poor
outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog.
47:701–706. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Mitani Y, Oue N, Hamai Y, et al: Histone
H3 acetylation is associated with reduced p21(WAF1/CIP1) expression
by gastric carcinoma. J Pathol. 205:65–73. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kouzarides T: Chromatin modifications and
their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Prystowsky MB, Adomako A, Smith RV, et al:
The histone deacetylase inhibitor LBH589 inhibits expression of
mitotic genes causing G2/M arrest and cell death in head and neck
squamous cell carcinoma cell lines. J Pathol. 218:467–477. 2009.
View Article : Google Scholar
|
|
9.
|
Ohm JE, McGarvey KM, Yu X, et al: A stem
cell-like chromatin pattern may predispose tumor suppressor genes
to DNA hypermethylation and heritable silencing. Nat Genet.
39:237–242. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Schlesinger Y, Straussman R, Keshet I, et
al: Polycomb-mediated methylation on Lys27 of histone H3 pre-marks
genes for de novo methylation in cancer. Nat Genet. 39:232–236.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Vire E, Brenner C, Deplus R, et al: The
Polycomb group protein EZH2 directly controls DNA methylation.
Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Karlic R, Chung HR, Lasserre J, Vlahovicek
K and Vingron M: Histone modification levels are predictive for
gene expression. Proc Natl Acad Sci USA. 107:2926–2931. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Yoo KH and Hennighausen L: EZH2
methyltransferase and H3K27 methylation in breast cancer. Int J
Biol Sci. 8:59–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Cai MY, Hou JH, Rao HL, et al: High
expression of H3K27me3 in human hepatocellular carcinomas
correlates closely with vascular invasion and predicts worse
prognosis in patients. Mol Med. 17:12–20. 2011.
|
|
15.
|
Ellinger J, Kahl P, von der Gathen J, et
al: Global histone H3K27 methylation levels are different in
localized and metastatic prostate cancer. Cancer Invest. 30:92–97.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Anderton JA, Bose S, Vockerodt M, et al:
The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus
and over-expressed in Hodgkin’s lymphoma. Oncogene. 30:2037–2043.
2011.PubMed/NCBI
|
|
17.
|
Tzao C, Tung HJ, Jin JS, et al: Prognostic
significance of global histone modifications in resected squamous
cell carcinoma of the esophagus. Mod Pathol. 22:252–260. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Cai MY, Tong ZT, Zhu W, et al: H3K27me3
protein is a promising predictive biomarker of patients’ survival
and chemoradioresistance in human nasopharyngeal carcinoma. Mol
Med. 17:1137–1145. 2011.PubMed/NCBI
|
|
19.
|
Chase A and Cross NC: Aberrations of EZH2
in cancer. Clin Cancer Res. 17:2613–2618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Takawa M, Masuda K, Kunizaki M, et al:
Validation of the histone methyltransferase EZH2 as a therapeutic
target for various types of human cancer and as a prognostic
marker. Cancer Sci. 102:1298–1305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Huqun, Ishikawa R, Zhang J, et al:
Enhancer of zeste homolog 2 is a novel prognostic biomarker in
nonsmall cell lung cancer. Cancer. 118:1599–1606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Gong Y, Huo L, Liu P, et al: Polycomb
group protein EZH2 is frequently expressed in inflammatory breast
cancer and is predictive of worse clinical outcome. Cancer.
117:5476–5484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kleer CG, Cao Q, Varambally S, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Chang CJ, Yang JY, Xia W, et al: EZH2
promotes expansion of breast tumor initiating cells through
activation of RAF1-beta-catenin signaling. Cancer Cell. 19:86–100.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Kunju LP, Cookingham C, Toy KA, Chen W,
Sabel MS and Kleer CG: EZH2 and ALDH-1 mark breast epithelium at
risk for breast cancer development. Mod Pathol. 24:786–793. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Alford SH, Toy K, Merajver SD and Kleer
CG: Increased risk for distant metastasis in patients with familial
early-stage breast cancer and high EZH2 expression. Breast Cancer
Res Treat. 132:429–437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Bachmann IM, Halvorsen OJ, Collett K, et
al: EZH2 expression is associated with high proliferation rate and
aggressive tumor subgroups in cutaneous melanoma and cancers of the
endometrium, prostate, and breast. J Clin Oncol. 24:268–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Fujii S, Fukamachi K, Tsuda H, Ito K, Ito
Y and Ochiai A: RAS oncogenic signal upregulates EZH2 in pancreatic
cancer. Biochem Biophys Res Commun. 417:1074–1079. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Guo J, Cai J, Yu L, Tang H, Chen C and
Wang Z: EZH2 regulates expression of p57 and contributes to
progression of ovarian cancer in vitro and in vivo. Cancer Sci.
102:530–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Koji T, Kondo S, Hishikawa Y, An S and
Sato Y: In situ detection of methylated DNA by histo
endonuclease-linked detection of methylated DNA sites: a new
principle of analysis of DNA methylation. Histochem Cell Biol.
130:917–925. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
An S, Hishikawa Y and Koji T: Induction of
cell death in rat small intestine by ischemia reperfusion:
differential roles of Fas/Fas ligand and Bcl-2/Bax systems
depending upon cell types. Histochem Cell Biol. 123:249–261. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Shirendeb U, Hishikawa Y, Moriyama S, et
al: Human papillomavirus infection and its possible correlation
with p63 expression in cervical cancer in Japan, Mongolia, and
Myanmar. Acta Histochem Cytochem. 42:181–190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Song N, Liu J, An S, Nishino T, Hishikawa
Y and Koji T: Immunohistochemical analysis of histone H3
modifications in germ cells during mouse spermatogenesis. Acta
Histochem Cytochem. 44:183–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Adams JC: Heavy metal intensification of
DAB-based HRP reaction product. J Histochem Cytochem. 29:7751981.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Yamayoshi T, Nagayasu T, Matsumoto K, Abo
T, Hishikawa Y and Koji T: Expression of keratinocyte growth
factor/fibroblast growth factor-7 and its receptor in human lung
cancer: correlation with tumour proliferative activity and patient
prognosis. J Pathol. 204:110–118. 2004. View Article : Google Scholar
|
|
36.
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: a new bioinformatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Rogenhofer S, Kahl P, Mertens C, et al:
Global histone H3 lysine 27 (H3K27) methylation levels and their
prognostic relevance in renal cell carcinoma. BJU Int. 109:459–465.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Holm K, Grabau D, Lovgren K, et al: Global
H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
Mol Oncol. 6:494–506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Chen H, Tu SW and Hsieh JT:
Down-regulation of human DAB2IP gene expression mediated by
polycomb Ezh2 complex and histone deacetylase in prostate cancer. J
Biol Chem. 280:22437–22444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Kuzmichev A, Margueron R, Vaquero A, et
al: Composition and histone substrates of polycomb repressive group
complexes change during cellular differentiation. Proc Natl Acad
Sci USA. 102:1859–1864. 2005. View Article : Google Scholar
|
|
41.
|
Cao R and Zhang Y: The functions of
E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr
Opin Genet Dev. 14:155–164. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Kuzmichev A, Jenuwein T, Tempst P and
Reinberg D: Different EZH2-containing complexes target methylation
of histone H1 or nucleosomal histone H3. Mol Cell. 14:183–193.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Molloy PL and Watt F: DNA methylation and
specific protein-DNA interactions. Philos Trans R Soc Lond B Biol
Sci. 326:267–275. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Ross JP, Rand KN and Molloy PL:
Hypomethylation of repeated DNA sequences in cancer. Epigenomics.
2:245–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Digel W and Lubbert M: DNA methylation
disturbances as novel therapeutic target in lung cancer:
preclinical and clinical results. Crit Rev Oncol Hematol. 55:1–11.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT
and Wang YC: Alteration of DNA methyltransferases contributes to
5′CpG methylation and poor prognosis in lung cancer. Lung Cancer.
55:205–213. 2007.
|
